GYRE
GYRE THERAPEUTICS, INC.
A free key covers every company here: 1,000 calls a month, no card.
What it owns, and who has a claim on it
Both columns are the same height because they are the same money, counted twice: once by what it is, once by who it belongs to.
| Cash | $42M21% |
|---|---|
| Receivables | $33M16% |
| Inventory | $12M6% |
| Property & equipment | $27M13% |
| Other assetsincludes 2 line items this filer does not report separately | $88M44% |
| Accounts payable | $3M1% |
|---|---|
| Other liabilitiesincludes 1 line item this filer does not report separately | $33M16% |
| Equity incl. noncontrolling interest | $145M72% |
| Not read from this filingThis filer's own stated total for liabilities plus equity equals their total assets, so the filing balances against its own arithmetic. This band is the part this page did not read. Whether that line is tagged under a name this site does not map, tagged only with a dimension, or not tagged in the filing's XBRL cannot be told from the figures held here. | $22M11% |
Not reported separately
This filer does not break these out. They are inside the totals, counted in the shaded remainder — not estimated, and not set to zero.
GYRE THERAPEUTICS, INC. (GYRE) files with the SEC as a health care company. Its most recent balance sheet puts total assets at $201M, against $35M of liabilities and $145M of equity, as at 2026-09-30. That balance sheet grew 1.0% against 2026-06-30, when total assets were $199M. Liabilities account for 17.5% of the balance sheet and equity 71.8%, about $0.24 of liabilities for every dollar of equity. The largest single line on the asset side is Cash at $42M, 20.7% of total assets, followed by Receivables at $33M. Its largest single liability is Accounts payable at $3M, 1.3% of the balance sheet. The figures come from a filing filed on 2026-11-06. Some line items this filer reports are not broken out separately here; the totals are complete and the difference is shown as a remainder rather than distributed across the lines that are named. As filed, GYRE THERAPEUTICS, INC.'s stated liabilities plus equity equals its total assets — the balance sheet balances, and the filer's own arithmetic is sound. The components this page reads fall 10.7% short of that stated total, so something on the credit side is not reaching this page: either tagged under a name this site does not read, or not tagged in the filing's XBRL at all. Those are indistinguishable from here, so the shortfall is shown as read rather than filled in. Every figure above is as filed, taken from the most recent filing that reported it. Nothing is estimated or smoothed, and where the filing and the identity disagree the disagreement is shown rather than closed.
It is mostly owner-funded: equity is 72% of the balance sheet, borrowings and other claims the rest.
Not every line item is reported separately by this filer: goodwill, intangibles, long-term debt are inside the totals rather than broken out.
The numbers behind GYRE THERAPEUTICS, INC.’s balance sheet
The check, written out
Assets $201,251,000 − (liabilities $35,183,000 + equity $144,517,000) = $21,551,000
The filer's own stated total for liabilities and equity is $201,251,000; that equals its total assets, so the filing balances against its own arithmetic and the difference is what this site did not read.
Ratios
| Liabilities to assets | $35M ÷ $201M | 17.5% |
|---|---|---|
| Equity to assets | $145M ÷ $201M | 71.8% |
| Liabilities to equity | $35M ÷ $145M | 0.24× |
| Largest asset line: Cash | $42M ÷ $201M | 20.7% |
| Largest liability line: Accounts payable | $3M ÷ $201M | 1.3% |
Does it balance, quarter by quarter
5 of the last 8 tested balance sheets on file reconcile as this site reads them. Each row is judged by the same check as the drawing above, and “latest filing” is the newest filing that carried that period's figures, since later filings repeat earlier periods as comparatives.
| Period end | Latest filing | Assets | Liabilities | Equity | A = L + E |
|---|---|---|---|---|---|
| 2026-09-30 | 2026-11-06 | $201M | $35M | $145M | Filer's own totals agree; we read 10.7% less than its stated total |
| 2026-06-30 | 2026-08-07 | $199M | $34M | $142M | Filer's own totals agree; we read 11.3% less than its stated total |
| 2026-03-31 | 2026-05-08 | $162M | $25M | $101M | Balanced, with noncontrolling interest |
| 2025-12-31 | 2026-08-07 | $220M | $31M | $60M | Filer's own totals agree; we read 58.6% less than its stated total |
| 2025-09-30 | 2025-11-07 | $159M | $22M | $137M | Balanced |
| 2025-06-30 | 2025-08-11 | $153M | $23M | $92M | Balanced, with noncontrolling interest |
| 2025-03-31 | 2025-05-09 | $130M | $25M | $68M | Balanced, with noncontrolling interest |
| 2024-12-31 | 2025-03-17 | $125M | $27M | $63M | Balanced, with noncontrolling interest |
Where to go from here
- All Health Care companies — largest by total assets first, as most recently filed.
- Every company covered — the directory this page belongs to.
- How the check works — what “balanced” means and what the exceptions are.
Ask about these numbers
Answered from the figures on this page and nothing else. Ask for something that is not here — another company, a share price, an earlier quarter — and it will tell you it is not in the filing data.
This is a language model reading the same numbers you can see. It does not predict, rate or recommend.
Learn more
- What Is the Accounting Identity? Meaning and Example — Why Assets = Liabilities + Equity works as a test on data you did not produce, and what it means when a filing does not balance.
- Why Naive XBRL Extraction Breaks Balance Sheets (And How a Balance Check Catches It) — How the figure on this page was chosen out of the twenty-odd tags the filer published for it.
- 995 of 38,568 SEC Filings Failed Our Balance Sheet Check — 995 of 38,568 filings failed the check: the method, the reasons and the filings themselves.
Every figure here is also available as JSON — the API reference and what it costs.
Related companies
The nearest in size that file in the same sector, each drawn to the same scale.